Supplements
Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: July 14th, 2011 - July 14th, 2012

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.


Target Audience
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma (MM).


Educational Objectives
After completing this activity, the participant should be better able to:

  • Evaluate the efficacy and safety of standard and novel MM therapies for patients ineligible for stem cell transplant
  • Review the clinical impact of modified dosing schedules in elderly patients with MM who are unable to undergo stem cell transplant
  • Describe current evidence-based recommendations related to the selection, timing, and sequencing of therapies for nontransplant patients with MM

Agenda - 1.25 hours
• Articles/Commentaries: 60 minutes
• Evaluation/Post-Test: 15 minutes


Physician Continuing Education Accreditation
This activity has been planned and implemented in accordance with the  Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation
Global designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.


Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-11-031-H01-P.

For questions regarding the physician accreditation of this activity, please contact Global at (303) 395-1782 or This email address is being protected from spambots. You need JavaScript enabled to view it..

For questions regarding the nursing and pharmacy accreditation of this activity, please contact MLI at (609) 333-1693 or This email address is being protected from spambots. You need JavaScript enabled to view it..


Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Faculty Disclosures
*William Bensinger, MD, is a consultant for and has received contract research from for Celgene, Millennium Pharmaceuticals, Inc., and Onyx, and is on the speakers’ bureau for Celgene.

Kathryn Lilleby, RN, has nothing to disclose.

Tara L. Chen, PharmD, BCOP, has nothing to disclose.

*Sagar Lonial, MD is a consultant for Bristol-Myers Squibb,  Celgene, Merck, Millennium Pharmaceuticals, Inc., Novartis, and Onyx.

*Content will include non-FDA-approved uses.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Name of Planner
or Manager
Company Reported Financial
Relationship
Dana Delibovi COEXM Nothing to disclose
Jackie Dawson, MSN Global Nothing to disclose
Amanda Glazar, PhD Global Nothing to disclose
Nancy Nesser, JD, PharmD MLI Nothing to disclose
Ryan Sims, CRNA, MS MLI Nothing to disclose

Disclaimer
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Related Items
Recent Advances In The Treatment Of Multiple Myeloma: Proceedings From a Post-ASH Roundtable
Paul Richardson, MD, Kenneth C. Anderson, MD, William Bensinger, MD, Jesús San Miguel, MD, Evangelos Terpos, MD, PhD
Supplements published on March 2, 2011
Conference Faculty Perspectives: Highlights From ASCO 2010
Paul Richardson, MD, William Bensinger, MD, Kenneth C. Anderson, MD, Melissa Alsina, MD, Jonathan Kaufman, MD
Supplements published on August 13, 2010
Conference Faculty Perspectives: Highlights From an International Hematology/Oncology Meeting
Paul Richardson, MD, William Bensinger, MD, Michelle Cavo, MD, Jean-Luc Harousseau, MD, Sundar Jagannath, MD
Supplements published on February 11, 2010
Considerations in Multiple Myeloma: Stem Cell Mobilization
Sagar Lonial, MD, William Bensinger, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN
Supplements published on August 31, 2009
Last modified: March 21, 2014